NK-1受体拮抗剂全称神经激肽-1受体拮抗剂,英文名neurokinin-1 receptor antagonists(NK-1 RA)。NK-1受体在大脑呕吐中枢含量最高,P物质(substance P,SP)通过与NK-1受体强力结合激发呕吐、焦虑、偏头痛等一系列病生理过程,因此 NK-1受体拮抗剂可通过高选择性与NK-1受体结合,阻断 P物质的作用,降低CINV的发生率。
Chapter 41. NK1 Receptor Antagonists Potential Analgesics?Chas Bountra
速激肽受体1(TACR1)重组蛋白 Recombinant Tachykinin Receptor 1 (TACR1) NK1R; SPR; NKIR; TAC1R; Neurokinin 1 Receptor; Substance P Receptor来源:原核表达宿主:E.coli内毒素水平:<1.0EU/µg(LAL法测定)亚细胞定位:分泌预测分子量:14.9kDa实际分子量:17kDa(差异分析请参阅说明书)...
NK1(substanceP)receptor LauraEGoldsmith1,MadanMKwatra1 ReviewArticle OpenAccess Neurokinin-1receptor(NK1R),orsubstancePreceptor,isaGprotein-coupledreceptor(GPCR)thattransmitsthesignalof substanceP(SP)andothertachykinins.UponstimulationbyitsagonistSP,NK1RhasbeenshowntointeractwithmultipleG proteins,includingGs...
NK-1 Antagonist 1 是一种神经激肽-1 受体 (NK-1 receptor) 拮抗剂,可用于 NK-1 相关的疾病研究,包括咳嗽、膀胱过度活动症、酒精依赖和压抑等。 NK-1拮抗剂1名称 中文名NK-1拮抗剂1 英文名NK-1 Antagonist 1 NK-1拮抗剂1物理化学性质 分子式C25H23F6N5O2 ...
5.Trower, M; Anderson, RA; Ballantyne, E, et al. (2020). Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Meno...
Anti-Neurokinin 1 Receptor (NK1R) (extracellular)-ATTO Fluor-488 Antibody - 50 μl 价格: 价格电议 产品详情:温馨提示:优宁维所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)! ... 纯度:见优宁维官网% 包装规格:见优宁维官网 用途:详见说明书 用途:...
[Keywords]Araipitan;Antiemetic;NK1ReceptorAntagonists 新视野NewHorizons 22药品评价2016年第13卷第10期 健康中国受试者接受阿瑞匹坦125mg单次口 服制剂(第1天)或者阿瑞匹坦3天治疗立案(包括 第1天125mg单次口服以及第2～3天80mg单次口 服),阿瑞匹坦的中位T ...
Reference work entry First Online:01 January 2018 pp 3445 Cite this reference work entry Encyclopedia of Signaling Molecules 111Accesses Neurokinin-1 Receptor Editor information Editors and Affiliations Department of Molecular Science and Technology, Ajou University, Suwon, Korea ...
5.Trower, M; Anderson, RA; Ballantyne, E, et al. (2020). Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Meno...